Moderna struggles laid bare by CEO admissions
The challenge of maintaining the earlier growth achieved by US mRNA medicines specialist Moderna (Nasdaq: MRNA) through its COVID vaccine Spikevax was always going to be very difficult, and chief executive Stéphane Bancel has admitted that it is proving to be just that.
Mr Bancel wrote to shareholders to offer a reflection of his thoughts on 2024, accepting that the past year brought “formidable challenges for Moderna along with significant advances, particularly for the development pipeline.”
His letter, published on Monday, adds: “It was a year of navigating a dynamic global landscape and evolving commercial realities, demanding resilience, innovation and adaptability.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze